EPA:ALTHE - Euronext Paris - Matif - FR0010120402 - Common Stock - Currency: EUR
EPA:ALTHE (5/8/2025, 7:00:00 PM)
0.24
+0 (+1.48%)
The current stock price of ALTHE.PA is 0.24 EUR. In the past month the price increased by 47.69%. In the past year, price decreased by -54.02%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABL.DE | ABBOTT LABORATORIES | 28.2 | 206.87B | ||
IUI1.DE | INTUITIVE SURGICAL INC | 71.18 | 172.45B | ||
BSX.DE | BOSTON SCIENTIFIC CORP | 38.91 | 137.55B | ||
2M6.DE | MEDTRONIC PLC | 15.79 | 95.77B | ||
SHL.DE | SIEMENS HEALTHINEERS AG | 20.92 | 53.08B | ||
BOX.DE | BECTON DICKINSON AND CO | 11.99 | 42.93B | ||
EWL.DE | EDWARDS LIFESCIENCES CORP | 29.24 | 39.54B | ||
DC4.DE | DEXCOM INC | 51.58 | 29.53B | ||
1PHIA.MI | KONINKLIJKE PHILIPS NV | 16.09 | 21.02B | ||
PHIA.AS | KONINKLIJKE PHILIPS NV | 16.07 | 20.55B | ||
PHI1.DE | KONINKLIJKE PHILIPS NV | 15.48 | 20.23B | ||
BIM.PA | BIOMERIEUX | 30.13 | 13.77B |
Théraclion SA develops, manufactures, and markets oncological medical equipment. The company is headquartered in Malakoff, Ile-De-France. The company went IPO on 2014-04-25. The firm is a a spin-off of Inserm and EDAPTechomed. The main activity of the Company is developping, manufacturing and marketing echotherapy medical equipments associating therapy by focused ultrasound and monitoring by ultrasound. The firm provides Echopulse, a device for the non-invasive and outpatient treatment of the fibroadenoma of the breast and thyroid nodules.
THERACLION
244, avenue Pierre Brossolette
Malakoff ILE-DE-FRANCE FR
Employees: 28
Phone: 33155489070
The current stock price of ALTHE.PA is 0.24 EUR. The price increased by 1.48% in the last trading session.
The exchange symbol of THERACLION is ALTHE and it is listed on the Euronext Paris - Matif exchange.
ALTHE.PA stock is listed on the Euronext Paris - Matif exchange.
THERACLION (ALTHE.PA) has a market capitalization of 11.12M EUR. This makes ALTHE.PA a Nano Cap stock.
THERACLION (ALTHE.PA) currently has 28 employees.
THERACLION (ALTHE.PA) has a resistance level at 0.29. Check the full technical report for a detailed analysis of ALTHE.PA support and resistance levels.
The Revenue of THERACLION (ALTHE.PA) is expected to grow by 50% in the next year. Check the estimates tab for more information on the ALTHE.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALTHE.PA does not pay a dividend.
THERACLION (ALTHE.PA) will report earnings on 2025-10-28.
THERACLION (ALTHE.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.09).
ChartMill assigns a technical rating of 5 / 10 to ALTHE.PA. When comparing the yearly performance of all stocks, ALTHE.PA is a bad performer in the overall market: 93.29% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to ALTHE.PA. While ALTHE.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months ALTHE.PA reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS increased by 32.6% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -29.91% | ||
ROE | -162.93% | ||
Debt/Equity | 0.62 |
ChartMill assigns a Buy % Consensus number of 87% to ALTHE.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.